Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology ExpertiseMORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health®…
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial…
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec…
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396…
Data presented at the American Diabetes Association 83rd Scientific SessionsPHILADELPHIA, June 24, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held,…
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an…
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on…
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a…
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an…
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a…